CEU Statement: Depot Medroxyprogesterone Acetate (DMPA, Depo- Provera) and Risk of HIV Acquisition (January 2015)

Published on: 1 January 2015

File size: 297kb PDF

File type: Clinical Statements

Author: FSRH Clinical Effectiveness Unit (CEU)

Progestogen-only injectable contraception is widely used across the world and is particularly popular in resource poor countries with a high incidence of HIV infection e.g. in sub-Saharan Africa. It is clearly important therefore to establish whether there is any relationship between the use of injectable contraception and increased risk of HIV acquisition.

Your download should start automatically. If not download directly.